Navigation Links
Landauer, Inc. Reports Fiscal 2011 Second Quarter Results
Date:5/3/2011

ously reported change in the supply relationship between Landauer and Nagase Landauer, which converted its customer base from Luxel to the InLight technology during fiscal 2010.  Nagase Landauer no longer purchases service badges from the Company.  The historical Luxel badge revenues were partially replaced by a royalty arrangement, resulting in no corresponding impact on net income.  Without the Nagase Landauer impact, domestic Radiation Monitoring revenues declined 6 percent, or $1.2 million, driven by lower non-recurring InLight equipment sales, primarily to the Canadian government agency responsible for occupational monitoring and radiation emergency preparedness for the citizens of Canada.  International Radiation Monitoring revenues increased 14 percent, or $1.0 million, on organic growth in most regions and the strengthening of most foreign currencies against the dollar.

Radiation Monitoring gross margin for the second fiscal quarter of 2011 increased to 71 percent from 68 percent in the year ago period, primarily due to the decline in lower margin sales to Nagase Landauer.  Selling, general and administrative costs for the second fiscal quarter of 2011 increased 3 percent, or $0.2 million, to $7.4 million.  The increase is due primarily to the strengthening of most foreign currencies against the dollar.  Operating income, inclusive of the impact of acquisition related transaction and reorganization costs, for the second fiscal quarter of 2011 increased 2 percent, or $0.2 million, to $12.1 million compared with operating income of $11.9 million for fiscal 2010.

Medical Physics SegmentMedical Physics revenues for the second fiscal quarter of 2011 increased 40 percent, or $1.4 million, to $4.8 million on $0.7 million of organic growth and $0.7 million due to the impact of acquired companies.  The gross margin increased to 23 percent from 22 percent in the year ago period.  Selling, general and
'/>"/>

SOURCE Landauer, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Landauer, Inc. Appoints Two New Members to Board of Directors
2. Cynosure Reports Financial Results for the First Quarter of 2011
3. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
4. VIVUS Reports First Quarter 2011 Financial Results
5. Dendreon Reports First Quarter 2011 Financial Results
6. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
7. Nektar Therapeutics Reports First Quarter 2011 Financial Results
8. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
9. China Green Material Technologies, Inc. Reports 2010 Financial Results
10. GeneLink Reports Denial of Appeal
11. GeneLink Reports 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... BOXMEER, The Netherlands and LONDON, September 26 ,Nobilon ... care business,unit of Akzo Nobel, and Protherics PLC, ... cancer, today announced that Nobilon,has licensed Protherics, CoVaccine ... seasonal influenza vaccines in elderly people. More ...
... Empowers Life Sciences Community with accelerated BioInformatics, ... Corp., announced,the initiation of Progeniq Pte Ltd, ... Singapore, into the BioIT Alliance today. The,BioIT ... integrate science and,technology to accelerate the pace ...
... Tomorrow, Wednesday, September 26th at 8:30am, NEW YORK, ... announced today that it will conduct a conference call,to ... II portfolio,products for a territory outside the US. ... 2007, at,8:30am EDT. Michael S. Weiss, Chairman and CEO ...
Cached Biology Technology:Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 2Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications 3Progeniq Joins Microsoft in Bio IT Alliance 2Progeniq Joins Microsoft in Bio IT Alliance 3Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance 2
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... diseases are associated with defective proteins accumulating in ... mechanisms are not operating correctly. Now, researchers at ... discovered a molecular link between the cell’s two ... succeeded in using this link to rescue neurodegenerative ...
... Few older people die with brains untouched by a ... signs of dementia increases with the number of different ... new study. The research was funded by the National ... of Health, and conducted at the Rush Alzheimer’s Disease ...
... of the Roche group, and a Yale School of ... company’s Genome Sequencer™ system to identify previously undetectable rare ... performed clinical trial. The work, presented today by ... Medicine and the VA CT Health Care System, was ...
Cached Biology News:Penn researchers link cell's protein recycling systems 2Penn researchers link cell's protein recycling systems 3Study finds mix of disease processes at work in brains of most people with dementia 2454 sequencing identifies HIV drug resistance at early stage 2
... CAST Equine EIA Principle: ... LTD4 and LTE4 are products ... 5-lipoxygenase and glutathione-S-transferase. In the ... "Slow Reacting Substances of Anaphylaxis ...
... contain the basic components and protocol ... ELISA plates for quantitation of a ... cell culture supernate. Every Screening Set ... Standard (5 individual standards), Streptavidin-HRP, TMB ...
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Biology Products: